This “obesity-inflammation-aromatase axis” has been proposed to play an important role in increased risk of ER+ breast cancer in postmenopausal women, by elevating estrogen levels in the breasts of women in whom levels of estrogen in the general circulation are reduced (60, 64, 65). The gene discussed is CYP19A1; the disease is breast carcinoma.